公开(公告)号：US10809251B2

公开(公告)日：2020-10-20

申请号：US15903838

申请日：2018-02-23

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53 ,  G01N33/58

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20210041428A1

公开(公告)日：2021-02-11

申请号：US17069591

申请日：2020-10-13

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53 ,  G01N33/58

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20180180606A1

公开(公告)日：2018-06-28

申请号：US15903838

申请日：2018-02-23

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53

CPC classification number: G01N33/54306 ,  G01N33/53 ,  G01N33/5306 ,  G01N33/533 ,  G01N33/543 ,  G01N33/582

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20240302386A1

公开(公告)日：2024-09-12

申请号：US18258993

申请日：2021-12-21

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Haode Chen ,  Heng Wu ,  Hong Tan ,  Robert F. Zuk

IPC: G01N33/74 ,  G01N21/64 ,  G01N21/76

CPC classification number: G01N33/74 ,  G01N21/6428 ,  G01N21/76 ,  G01N2021/6439 ,  G01N2333/585

Abstract: The present invention is directed to an immunoassay method for detecting an analyte in a liquid sample; and provides accuracy and reproducibility for both high concentration and low concentration samples. The method uses both fluorescence marker and chemiluminescence marker, and reads both fluorescence signal and chemiluminescence signal. The analyte concentration is determined based on either a calibration curve for the fluorescence signal, or a calibration curve chemiluminescence signal, using a pre-established analyte concentration value.